Five Prime Therapeutics Highlights Presentation Of Data From Safety Lead-In To Phase 3 FIGHT Trial Of Bemarituzumab At 2019 American Society Of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
Benzinga Newsdesk